SPONSORED CONTENT
Demonstrate Compliance with 340B Drug Pricing Requirements, Implement Strategies for Successful Audits, and Provide Quality Care
Designed for both Covered Entities and Manufacturers, attend this event to explore the latest developments in 340B with regards to transparency, HRSA 340B audits and other federal oversight activities. Attendees
…
Companion bills in the Massachusetts House and Senate would restore the 340B program’s intent by stopping pharmacy benefit manager discrimination against any 340B covered entities and their contract pharmacies, the sponsor of the state Senate bill said during a recent
…
With so many advocacy groups using the term “340B” in their name these days, it’s easy to confuse one with another. Ted Slafsky’s latest column for Verity Solutions is a guide to the menagerie.
Slafsky, publisher and CEO of 340B
…
SPONSORED CONTENT
In 1999, the Centers for Disease Control and Prevention (CDC) launched the National Campaign to Eliminate Syphilis from the United States. The CDC updated its ambitious plan in 2006 and aimed to reduce rates of primary and secondary
…
In the episode “340B Insights: The Current State of the 340B Program,” RxStrategies’ Jonathan Ghenn and Rhodie Smith connect with Ted Slafsky, Publisher and CEO of the 340B Report to share information on what’s important to Covered Entities and pharmacy professionals who manage a 340B Program
…
SPONSORED CONTENT
Recent surveys confirm what those of you reading this know painfully well: Hospital and clinic pharmacies are struggling from the restrictions drug manufacturers are placing on 340B pricing at contract pharmacy sites. As the 340B world awaits another batch of court rulings
…
A judge’s decision in February to vacate the federal government’s letter telling AstraZeneca its 340B contract pharmacy policy is illegal was our top breaking news story of 2022.
Number two on the list (based on how often a story page
…
Medicare likely would pay 340B hospitals 106% of the average sales price (ASP) for Aduhelm—Biogen’s high-cost biologic drug for early-stage Alzheimer’s disease—for the first two or three years it is on the market, not the ASP minus 22.5% 340B hospital
…
*Sign up for news summaries and alerts from 340B Report
